<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00511797</url>
  </required_header>
  <id_info>
    <org_study_id>91615</org_study_id>
    <secondary_id>310283</secondary_id>
    <nct_id>NCT00511797</nct_id>
  </id_info>
  <brief_title>SH T00186 Phase II/ III Optimal Drospirenone (DRSP) Dose Finding and Placebo-controlled Comparative Study</brief_title>
  <official_title>A Multicenter, Double-blind, Randomized, Placebo-controlled Comparative Study to Investigate the Optimal Dose of Drospirenone for Dysmenorrhea With SH T04740A [Drospirenone 1 mg/Ethinylestradiol 20 µg (as ß-cyclodextrin Clathrate)], SH T 04740E [Drospirenone 2 mg/Ethinylestradiol 20 µg (as ß-cyclodextrin Clathrate)] and SH T00186D [Drospirenone 3 mg/ Ethinylestradiol 20 µg (as ß-cyclodextrin Clathrate)] Administered Orally for 16 Weeks (4 Cycles), and to Confirm the Efficacy of SH T00186D for Dysmenorrhea.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate efficacy of drospirenone for dysmenorrhea.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Total Dysmenorrheal Score at Final Evaluation</measure>
    <time_frame>Baseline and up to 4 Cycles (28 days per cycle)</time_frame>
    <description>Total dysmenorrheal score was defined as sum of 2 sub-scores: severity of dysmenorrhea (none: 0, mild: 1, moderate: 2, severe: 3) and use of analgesics (none: 0, mild: 1, moderate: 2, severe: 3). Total possible best is 0, and total possible worst is 6. Note: used with permission of Nobelpharma Co., Ltd. from the phase 3 clinical study protocol (Prog Med 2005:25 (3):739-758) of IKH-01 in dysmenorrhea (associated with endometriosis) (Nobelpharma Co., Ltd.)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Dysmenorrheal Score at Cycle 1 up to Cycle 4</measure>
    <time_frame>Baseline and up to 4 Cycles (28 days per cycle)</time_frame>
    <description>Total dysmenorrheal score was defined as sum of 2 sub-scores: severity of dysmenorrhea (none: 0, mild: 1, moderate: 2, severe: 3) and use of analgesics (none: 0, mild: 1, moderate: 2, severe: 3). Total possible best is 0, and total possible worst is 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Severity of Lower Abdominal Pain During Menstruation at Cycle 4</measure>
    <time_frame>Cycle 4 (28 days per cycle)</time_frame>
    <description>Severity of lower abdominal pain during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Severity of Low Back Pain During Menstruation at Cycle 4</measure>
    <time_frame>Cycle 4 (28 days per cycle)</time_frame>
    <description>Severity of low back pain during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Severity of Headache During Menstruation at Cycle 4</measure>
    <time_frame>Cycle 4 (28 days per cycle)</time_frame>
    <description>Severity of headache during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Severity of Nausea or Vomiting During Menstruation at Cycle 4</measure>
    <time_frame>Cycle 4 (28 days per cycle)</time_frame>
    <description>Severity of nausea or vomiting during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Total Pelvic Pain Score at Times Other Than During Menstruation at Cycle 4</measure>
    <time_frame>Cycle 4 (28 days per cycle)</time_frame>
    <description>Total pelvic pain score was defined as sum of 2 sub-scores: severity of dysmenorrhea and use of analgesics. Higher score means it is more severe. 0=None, 6=Severest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Visual Analogue Scale (VAS) for Dysmenorrhea at Times Other Than During Menstruation at Cycle 4</measure>
    <time_frame>From baseline up to Cycle 4 (28 days per cycle)</time_frame>
    <description>VAS is an unmarked scale on a line 100 mm in length, indicating from 0 mm (no pain) to 100 mm (worst pain a participant has ever experienced).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale (VAS) for Pelvic Pain at Times Other Than During Menstruation at Cycle 4</measure>
    <time_frame>Cycle 4 (28 days per cycle)</time_frame>
    <description>VAS is an unmarked scale on a line 100 mm in length, indicating from 0 mm (no pain) to 100 mm (worst pain a participant has ever experienced).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Endometrial Thickness After 4-cycle Treatment</measure>
    <time_frame>From baseline to Cycle 4 (28 days per cycle)</time_frame>
    <description>Endometrial thickness was measured via transvaginal ultrasound examination. The endometrium is the inner membrane of the uterus. During the menstrual cycle, the endometrium grows to a thick, blood vessel-rich, glandular tissue layer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Bleeding / Spotting Episodes</measure>
    <time_frame>For the first 90 days</time_frame>
    <description>Bleeding data were captured from the diary a participant recorded by herself. Bleeding is a genital bleeding. Spotting is a slight genital bleeding with participant's experience. An episode means a series of bleeding and/or spotting. The bleeding /spotting analyses are by intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Bleeding / Spotting Days</measure>
    <time_frame>For the first 90 days</time_frame>
    <description>Bleeding data were captured from the diary a participant recorded by herself. Bleeding is a genital bleeding. Spotting is a slight genital bleeding with participant's experience. The bleeding /spotting analyses are by intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Withdrawal Bleeding</measure>
    <time_frame>At Cycle 4 (28 days per cycle)</time_frame>
    <description>Withdrawal bleedings were defined as bleedings while a participant takes placebo tablets.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Intracyclic Bleeding</measure>
    <time_frame>At Cycle 4 (28 days per cycle)</time_frame>
    <description>Intracyclic bleedings were defined as bleedings while a participant takes active drugs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Non-heavy Intracyclic Bleeding</measure>
    <time_frame>At Cycle 4 (28 days per cycle)</time_frame>
    <description>Non-heavy bleedings were defined as those other than heavy bleeding (less or normal bleeding).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Non-heavy Withdrawal Bleeding</measure>
    <time_frame>At Cycle 4 (28 dyas per cycle)</time_frame>
    <description>Non-heavy bleedings were defined as those other than heavy bleeding (less or normal bleeding).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Carbohydrate Antigen-125 (CA125) After 4-cycle Treatment</measure>
    <time_frame>From baseline to Cycle 4 (28 days per cycle)</time_frame>
    <description>CA125 is a laboratory parameter giving an indication of having tumor, whose elevated levels that were defined by a lab suggest a potential tumor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum C-reactive Protein (CRP) After 4-cycle Treatment</measure>
    <time_frame>From baseline to Cycle 4 (28 days per cycle)</time_frame>
    <description>CRP is a laboratory parameter giving an indication of inflammation, whose elevated levels that were defined by a lab suggest a potential inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Estradiol Level After 4-cycle Treatment</measure>
    <time_frame>From baseline to Cycle 4 (28 days per cycle)</time_frame>
    <description>Estradiol is a predominant sex hormone that presents in female.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Progesterone Level at Cycle 4</measure>
    <time_frame>From baseline to Cycle 4 (28 days per cycle)</time_frame>
    <description>Progesterone is a steroid hormone involving in the female menstrual cycle, pregnancy, etc.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">249</enrollment>
  <condition>Dysmenorrhea</condition>
  <arm_group>
    <arm_group_label>DRSP 1 mg/EE 20 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 tablet per day Drospirenone (DRSP) 1 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DRSP 2 mg/EE 20 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 tablet per day Drospirenone (DRSP) 2 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DRSP 3 mg/EE 20 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 tablet per day placebo for 28 days in each 28-day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SH T04740B</intervention_name>
    <description>Drospirenone 1mg/EE 20µg (ß-CDC)</description>
    <arm_group_label>DRSP 1 mg/EE 20 μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SH T00186DF</intervention_name>
    <description>Drospirenone 3 mg/EE 20µg (ß-CDC)</description>
    <arm_group_label>DRSP 3 mg/EE 20 μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SH T04740F</intervention_name>
    <description>Drospirenone 2 mg/EE 20µg (ß-CDC)</description>
    <arm_group_label>DRSP 2 mg/EE 20 μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 20 years or older at obtaining informed consent

          -  Patients having the normal menstrual cycle (28+/-3 days) in the latest two menses
             before the final enrollment

          -  Patients having a total dysmenorrhea score of at least 3 points in two menstrual
             cycles before the final enrollment

        Exclusion Criteria:

          -  Patients with ovarian chocolate cysts and symptomatic uterine fibroids (as defined in
             greater detail in the study protocol)

          -  Patients with estrogen-dependent tumors (e.g. breast cancer, cancer of the uterine
             body or breast fibrocystic, etc.), and patients with cervical cancer or suspected
             cervical cancer (e.g. class III or greater in the cervical smear or endometrial smear
             examination.)

          -  Patients with undiagnosed abnormal vaginal bleeding

          -  Patients with thrombophlebitis, pulmonary embolism, cerebrovascular disease(including
             transient ischemic attack, etc.), or coronary artery disease(e.g. myocardial
             infarction and angina pectoris, etc.), or a history of those diseases

          -  Patients aged 35 years or older who smoke at least 15 cigarettes per day

          -  Patients with migraine accompanied by prodrome (e.g. scintillating scotoma or
             star-shaped scintillation)

          -  Patients with pulmonary hypertension or valvular heart disease complicated by atrial
             fibrillation, and patients with a history of subacute bacterial endocarditis

          -  Patients who are regularly taking nutritional products that contain St. John's Wort

          -  Patients who underwent surgical treatment for endometriosis by laparotomy, or
             laparoscopy within 2 months prior to screening

          -  Patients who need to use analgesics regularly for therapeutic objectives other than
             relief from the pain of dysmenorrhea during this study (occasional use permitted)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Maebashi</city>
        <state>Gunma</state>
        <zip>371-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>650-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nishinomiya</city>
        <state>Hyogo</state>
        <zip>663-8204</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>231-0861</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>981-0933</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0061</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hachioji</city>
        <state>Tokyo</state>
        <zip>192-0046</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Setagaya-ku</city>
        <state>Tokyo</state>
        <zip>156-0042</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Setagaya-ku</city>
        <state>Tokyo</state>
        <zip>157-0066</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toshima-ku</city>
        <state>Tokyo</state>
        <zip>171-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyoto</city>
        <zip>612-0064</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <zip>530-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <results_reference>
    <citation>Momoeda M, et al. Treatment of Functional and Organic Dysmenorrhea - Investigation of the Efficacy and Safety of Drospirenone/Ethinylestradiol Combination Tablet (YAZ). Sanka to Fujinka (Obstetrics and Gynecology), 2010: 77 (8) 977-88 (in Japanese)</citation>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2007</study_first_submitted>
  <study_first_submitted_qc>August 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2007</study_first_posted>
  <results_first_submitted>April 15, 2010</results_first_submitted>
  <results_first_submitted_qc>September 10, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 4, 2010</results_first_posted>
  <last_update_submitted>November 30, 2016</last_update_submitted>
  <last_update_submitted_qc>November 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dysmenorrhea</keyword>
  <keyword>Dysmenorrheal score</keyword>
  <keyword>Drospirenone</keyword>
  <keyword>DRSP</keyword>
  <keyword>Ethinylestradiol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dysmenorrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Drospirenone</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Full Analysis Set (FAS) consisted of all patients who received at least one dose of study drug. Patients were analyzed as treated.
FAS was the primary analysis set for all efficacy endpoints and safety analyses. Per Protocol Set (PPS) was a subgroup of the FAS. The PPS consisted of patients in the FAS who did not have major protocol deviations.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>DRSP 1 mg/EE 20 μg</title>
          <description>1 tablet per day Drospirenone (DRSP) 1 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
        </group>
        <group group_id="P2">
          <title>DRSP 2 mg/EE 20 μg</title>
          <description>1 tablet per day Drospirenone (DRSP) 2 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
        </group>
        <group group_id="P3">
          <title>DRSP 3 mg/EE 20 μg</title>
          <description>1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>1 tablet per day placebo for 28 days in each 28-day cycle</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="63"/>
                <participants group_id="P3" count="62"/>
                <participants group_id="P4" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Subjects Dispensed Drugs</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="63"/>
                <participants group_id="P3" count="61"/>
                <participants group_id="P4" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Subjects Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="61">FAS</participants>
                <participants group_id="P2" count="62">FAS</participants>
                <participants group_id="P3" count="61">FAS</participants>
                <participants group_id="P4" count="58">FAS</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="55"/>
                <participants group_id="P3" count="51"/>
                <participants group_id="P4" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Never dispensed</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study drug not taken</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Partially missing diary</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other (moving etc)</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DRSP 1 mg/EE 20 μg</title>
          <description>1 tablet per day Drospirenone (DRSP) 1 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
        </group>
        <group group_id="B2">
          <title>DRSP 2 mg/EE 20 μg</title>
          <description>1 tablet per day Drospirenone (DRSP) 2 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
        </group>
        <group group_id="B3">
          <title>DRSP 3 mg/EE 20 μg</title>
          <description>1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>1 tablet per day placebo for 28 days in each 28-day cycle</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="61"/>
            <count group_id="B2" value="62"/>
            <count group_id="B3" value="61"/>
            <count group_id="B4" value="58"/>
            <count group_id="B5" value="242"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.0" lower_limit="21" upper_limit="45"/>
                    <measurement group_id="B2" value="30.6" lower_limit="20" upper_limit="43"/>
                    <measurement group_id="B3" value="30.9" lower_limit="20" upper_limit="48"/>
                    <measurement group_id="B4" value="30.8" lower_limit="20" upper_limit="44"/>
                    <measurement group_id="B5" value="30.8" lower_limit="20" upper_limit="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="58"/>
                    <measurement group_id="B5" value="242"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diagnosis type</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Functional dysmenorrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Organic dysmenorrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Details of organic dysmenorrhea</title>
          <description>Not all participants had organic dysmenorrhea. Some of participants were diagnosed as having a multiple type of organic dysmenorrhea.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Endometriosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uterine fibroids</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uterine adenomyosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicornuate uterus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Average length of menstrual cycle</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.6" lower_limit="25" upper_limit="31"/>
                    <measurement group_id="B2" value="28.7" lower_limit="25" upper_limit="33"/>
                    <measurement group_id="B3" value="28.3" lower_limit="25" upper_limit="32"/>
                    <measurement group_id="B4" value="28.7" lower_limit="25" upper_limit="31"/>
                    <measurement group_id="B5" value="28.6" lower_limit="25" upper_limit="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.05" lower_limit="15.6" upper_limit="30.0"/>
                    <measurement group_id="B2" value="20.41" lower_limit="16.6" upper_limit="25.8"/>
                    <measurement group_id="B3" value="20.67" lower_limit="16.4" upper_limit="29.9"/>
                    <measurement group_id="B4" value="21.19" lower_limit="17.2" upper_limit="27.7"/>
                    <measurement group_id="B5" value="20.82" lower_limit="15.6" upper_limit="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Total Dysmenorrheal Score at Final Evaluation</title>
        <description>Total dysmenorrheal score was defined as sum of 2 sub-scores: severity of dysmenorrhea (none: 0, mild: 1, moderate: 2, severe: 3) and use of analgesics (none: 0, mild: 1, moderate: 2, severe: 3). Total possible best is 0, and total possible worst is 6. Note: used with permission of Nobelpharma Co., Ltd. from the phase 3 clinical study protocol (Prog Med 2005:25 (3):739-758) of IKH-01 in dysmenorrhea (associated with endometriosis) (Nobelpharma Co., Ltd.)</description>
        <time_frame>Baseline and up to 4 Cycles (28 days per cycle)</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>DRSP 1 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 1 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O2">
            <title>DRSP 2 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 2 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O3">
            <title>DRSP 3 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>1 tablet per day placebo for 28 days in each 28-day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Dysmenorrheal Score at Final Evaluation</title>
          <description>Total dysmenorrheal score was defined as sum of 2 sub-scores: severity of dysmenorrhea (none: 0, mild: 1, moderate: 2, severe: 3) and use of analgesics (none: 0, mild: 1, moderate: 2, severe: 3). Total possible best is 0, and total possible worst is 6. Note: used with permission of Nobelpharma Co., Ltd. from the phase 3 clinical study protocol (Prog Med 2005:25 (3):739-758) of IKH-01 in dysmenorrhea (associated with endometriosis) (Nobelpharma Co., Ltd.)</description>
          <population>FAS</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="1.52"/>
                    <measurement group_id="O2" value="-2.1" spread="1.51"/>
                    <measurement group_id="O3" value="-1.9" spread="1.63"/>
                    <measurement group_id="O4" value="-1.0" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Three null hypotheses were sequentially tested. H01: DRSP 3 mg &gt;= Placebo (Active is equal or less in decrease of score) vs H11: DRSP 3 mg &lt; Placebo (Active is greater in decrease of score), H02: DRSP 2 mg &gt;= Placebo vs H12: DRSP 2 mg &lt; Placebo, H03: DRSP 1 mg &gt;= Placebo vs H13: DRSP 1 mg &lt; Placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pre-defined sequential tests were applied to protect alpha inflation by multiplicity.</p_value_desc>
            <method>t-test, 1 sided</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-0.92</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.290</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.49</ci_lower_limit>
            <ci_upper_limit>-0.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Second null hypothesis was tested. H02: DRSP 2 mg &gt;= Placebo vs H12: DRSP 2 mg &lt; Placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 1 sided</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-1.10</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.277</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.64</ci_lower_limit>
            <ci_upper_limit>-0.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Third null hypotheses was tested. H03: DRSP 1 mg &gt;= Placebo vs H13: DRSP 1 mg &lt; Placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 1 sided</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-1.44</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.280</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.00</ci_lower_limit>
            <ci_upper_limit>-0.89</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Dysmenorrheal Score at Cycle 1 up to Cycle 4</title>
        <description>Total dysmenorrheal score was defined as sum of 2 sub-scores: severity of dysmenorrhea (none: 0, mild: 1, moderate: 2, severe: 3) and use of analgesics (none: 0, mild: 1, moderate: 2, severe: 3). Total possible best is 0, and total possible worst is 6.</description>
        <time_frame>Baseline and up to 4 Cycles (28 days per cycle)</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>DRSP 1 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 1 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O2">
            <title>DRSP 2 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 2 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O3">
            <title>DRSP 3 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>1 tablet per day placebo for 28 days in each 28-day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Dysmenorrheal Score at Cycle 1 up to Cycle 4</title>
          <description>Total dysmenorrheal score was defined as sum of 2 sub-scores: severity of dysmenorrhea (none: 0, mild: 1, moderate: 2, severe: 3) and use of analgesics (none: 0, mild: 1, moderate: 2, severe: 3). Total possible best is 0, and total possible worst is 6.</description>
          <population>FAS</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="1.40"/>
                    <measurement group_id="O2" value="-2.1" spread="1.49"/>
                    <measurement group_id="O3" value="-1.8" spread="1.67"/>
                    <measurement group_id="O4" value="-0.8" spread="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="1.40"/>
                    <measurement group_id="O2" value="-2.3" spread="1.57"/>
                    <measurement group_id="O3" value="-1.9" spread="1.50"/>
                    <measurement group_id="O4" value="-1.1" spread="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="1.34"/>
                    <measurement group_id="O2" value="-2.3" spread="1.52"/>
                    <measurement group_id="O3" value="-2.1" spread="1.34"/>
                    <measurement group_id="O4" value="-1.0" spread="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="1.55"/>
                    <measurement group_id="O2" value="-2.3" spread="1.41"/>
                    <measurement group_id="O3" value="-2.1" spread="1.54"/>
                    <measurement group_id="O4" value="-1.0" spread="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Test results of 3 mg DRSP and placebo at Cycle 4 are shown. 2-sided 95% confidence intervals were calculated. To keep consistency with 2-sided 95% confidence intervals, 2.5% 1-sided significance levels were used for the statistical tests.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 1 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.10</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.322</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.74</ci_lower_limit>
            <ci_upper_limit>-0.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 1 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.34</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.306</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.95</ci_lower_limit>
            <ci_upper_limit>-0.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 1 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.53</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.317</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.16</ci_lower_limit>
            <ci_upper_limit>-0.90</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Severity of Lower Abdominal Pain During Menstruation at Cycle 4</title>
        <description>Severity of lower abdominal pain during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).</description>
        <time_frame>Cycle 4 (28 days per cycle)</time_frame>
        <population>FAS (Participants with data at Cycle 4)</population>
        <group_list>
          <group group_id="O1">
            <title>DRSP 1 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 1 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O2">
            <title>DRSP 2 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 2 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O3">
            <title>DRSP 3 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>1 tablet per day placebo for 28 days in each 28-day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Severity of Lower Abdominal Pain During Menstruation at Cycle 4</title>
          <description>Severity of lower abdominal pain during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).</description>
          <population>FAS (Participants with data at Cycle 4)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Severity of Low Back Pain During Menstruation at Cycle 4</title>
        <description>Severity of low back pain during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).</description>
        <time_frame>Cycle 4 (28 days per cycle)</time_frame>
        <population>FAS (Participants with data at Cycle 4)</population>
        <group_list>
          <group group_id="O1">
            <title>DRSP 1 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 1 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O2">
            <title>DRSP 2 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 2 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O3">
            <title>DRSP 3 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>1 tablet per day placebo for 28 days in each 28-day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Severity of Low Back Pain During Menstruation at Cycle 4</title>
          <description>Severity of low back pain during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).</description>
          <population>FAS (Participants with data at Cycle 4)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Severity of Headache During Menstruation at Cycle 4</title>
        <description>Severity of headache during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).</description>
        <time_frame>Cycle 4 (28 days per cycle)</time_frame>
        <population>FAS (Participants with data at Cycle 4)</population>
        <group_list>
          <group group_id="O1">
            <title>DRSP 1 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 1 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O2">
            <title>DRSP 2 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 2 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O3">
            <title>DRSP 3 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>1 tablet per day placebo for 28 days in each 28-day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Severity of Headache During Menstruation at Cycle 4</title>
          <description>Severity of headache during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).</description>
          <population>FAS (Participants with data at Cycle 4)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Severity of Nausea or Vomiting During Menstruation at Cycle 4</title>
        <description>Severity of nausea or vomiting during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).</description>
        <time_frame>Cycle 4 (28 days per cycle)</time_frame>
        <population>FAS (Participants with data at Cycle 4)</population>
        <group_list>
          <group group_id="O1">
            <title>DRSP 1 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 1 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O2">
            <title>DRSP 2 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 2 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O3">
            <title>DRSP 3 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>1 tablet per day placebo for 28 days in each 28-day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Severity of Nausea or Vomiting During Menstruation at Cycle 4</title>
          <description>Severity of nausea or vomiting during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).</description>
          <population>FAS (Participants with data at Cycle 4)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="47"/>
                    <measurement group_id="O4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Total Pelvic Pain Score at Times Other Than During Menstruation at Cycle 4</title>
        <description>Total pelvic pain score was defined as sum of 2 sub-scores: severity of dysmenorrhea and use of analgesics. Higher score means it is more severe. 0=None, 6=Severest.</description>
        <time_frame>Cycle 4 (28 days per cycle)</time_frame>
        <population>FAS (Participants with data at Cycle 4)</population>
        <group_list>
          <group group_id="O1">
            <title>DRSP 1 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 1 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O2">
            <title>DRSP 2 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 2 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O3">
            <title>DRSP 3 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>1 tablet per day placebo for 28 days in each 28-day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Total Pelvic Pain Score at Times Other Than During Menstruation at Cycle 4</title>
          <description>Total pelvic pain score was defined as sum of 2 sub-scores: severity of dysmenorrhea and use of analgesics. Higher score means it is more severe. 0=None, 6=Severest.</description>
          <population>FAS (Participants with data at Cycle 4)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Visual Analogue Scale (VAS) for Dysmenorrhea at Times Other Than During Menstruation at Cycle 4</title>
        <description>VAS is an unmarked scale on a line 100 mm in length, indicating from 0 mm (no pain) to 100 mm (worst pain a participant has ever experienced).</description>
        <time_frame>From baseline up to Cycle 4 (28 days per cycle)</time_frame>
        <population>FAS (Participants with data at Cycle 4)</population>
        <group_list>
          <group group_id="O1">
            <title>DRSP 1 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 1 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O2">
            <title>DRSP 2 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 2 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O3">
            <title>DRSP 3 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>1 tablet per day placebo for 28 days in each 28-day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Visual Analogue Scale (VAS) for Dysmenorrhea at Times Other Than During Menstruation at Cycle 4</title>
          <description>VAS is an unmarked scale on a line 100 mm in length, indicating from 0 mm (no pain) to 100 mm (worst pain a participant has ever experienced).</description>
          <population>FAS (Participants with data at Cycle 4)</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-43.0" spread="23.44"/>
                    <measurement group_id="O2" value="-39.5" spread="22.12"/>
                    <measurement group_id="O3" value="-31.8" spread="23.55"/>
                    <measurement group_id="O4" value="-10.3" spread="24.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analogue Scale (VAS) for Pelvic Pain at Times Other Than During Menstruation at Cycle 4</title>
        <description>VAS is an unmarked scale on a line 100 mm in length, indicating from 0 mm (no pain) to 100 mm (worst pain a participant has ever experienced).</description>
        <time_frame>Cycle 4 (28 days per cycle)</time_frame>
        <population>FAS (Participants with data at Cycle 4)</population>
        <group_list>
          <group group_id="O1">
            <title>DRSP 1 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 1 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O2">
            <title>DRSP 2 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 2 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O3">
            <title>DRSP 3 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>1 tablet per day placebo for 28 days in each 28-day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analogue Scale (VAS) for Pelvic Pain at Times Other Than During Menstruation at Cycle 4</title>
          <description>VAS is an unmarked scale on a line 100 mm in length, indicating from 0 mm (no pain) to 100 mm (worst pain a participant has ever experienced).</description>
          <population>FAS (Participants with data at Cycle 4)</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="11.52"/>
                    <measurement group_id="O2" value="5.4" spread="11.78"/>
                    <measurement group_id="O3" value="4.0" spread="14.26"/>
                    <measurement group_id="O4" value="11.5" spread="20.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Endometrial Thickness After 4-cycle Treatment</title>
        <description>Endometrial thickness was measured via transvaginal ultrasound examination. The endometrium is the inner membrane of the uterus. During the menstrual cycle, the endometrium grows to a thick, blood vessel-rich, glandular tissue layer.</description>
        <time_frame>From baseline to Cycle 4 (28 days per cycle)</time_frame>
        <population>FAS (Participants with data at Cycle 4)</population>
        <group_list>
          <group group_id="O1">
            <title>DRSP 1 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 1 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O2">
            <title>DRSP 2 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 2 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O3">
            <title>DRSP 3 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>1 tablet per day placebo for 28 days in each 28-day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Endometrial Thickness After 4-cycle Treatment</title>
          <description>Endometrial thickness was measured via transvaginal ultrasound examination. The endometrium is the inner membrane of the uterus. During the menstrual cycle, the endometrium grows to a thick, blood vessel-rich, glandular tissue layer.</description>
          <population>FAS (Participants with data at Cycle 4)</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.5" spread="4.11"/>
                    <measurement group_id="O2" value="-7.1" spread="3.25"/>
                    <measurement group_id="O3" value="-6.3" spread="4.07"/>
                    <measurement group_id="O4" value="-0.1" spread="2.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Bleeding / Spotting Episodes</title>
        <description>Bleeding data were captured from the diary a participant recorded by herself. Bleeding is a genital bleeding. Spotting is a slight genital bleeding with participant's experience. An episode means a series of bleeding and/or spotting. The bleeding /spotting analyses are by intensity.</description>
        <time_frame>For the first 90 days</time_frame>
        <population>FAS (Participants with the defined data)</population>
        <group_list>
          <group group_id="O1">
            <title>DRSP 1 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 1 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O2">
            <title>DRSP 2 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 2 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O3">
            <title>DRSP 3 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>1 tablet per day placebo for 28 days in each 28-day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Bleeding / Spotting Episodes</title>
          <description>Bleeding data were captured from the diary a participant recorded by herself. Bleeding is a genital bleeding. Spotting is a slight genital bleeding with participant's experience. An episode means a series of bleeding and/or spotting. The bleeding /spotting analyses are by intensity.</description>
          <population>FAS (Participants with the defined data)</population>
          <units>number of episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>bleeding / spotting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="0.9"/>
                    <measurement group_id="O2" value="3.3" spread="1.3"/>
                    <measurement group_id="O3" value="3.4" spread="0.9"/>
                    <measurement group_id="O4" value="2.9" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>bleeding only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.9"/>
                    <measurement group_id="O2" value="0.4" spread="0.8"/>
                    <measurement group_id="O3" value="0.3" spread="0.5"/>
                    <measurement group_id="O4" value="0.4" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>spotting only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.6"/>
                    <measurement group_id="O2" value="0.4" spread="1.1"/>
                    <measurement group_id="O3" value="0.4" spread="0.8"/>
                    <measurement group_id="O4" value="0.2" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Bleeding / Spotting Days</title>
        <description>Bleeding data were captured from the diary a participant recorded by herself. Bleeding is a genital bleeding. Spotting is a slight genital bleeding with participant's experience. The bleeding /spotting analyses are by intensity.</description>
        <time_frame>For the first 90 days</time_frame>
        <population>FAS (Participants with the defined data)</population>
        <group_list>
          <group group_id="O1">
            <title>DRSP 1 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 1 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O2">
            <title>DRSP 2 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 2 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O3">
            <title>DRSP 3 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>1 tablet per day placebo for 28 days in each 28-day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Bleeding / Spotting Days</title>
          <description>Bleeding data were captured from the diary a participant recorded by herself. Bleeding is a genital bleeding. Spotting is a slight genital bleeding with participant's experience. The bleeding /spotting analyses are by intensity.</description>
          <population>FAS (Participants with the defined data)</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>bleeding / spotting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.3" spread="8.7"/>
                    <measurement group_id="O2" value="31.2" spread="11.4"/>
                    <measurement group_id="O3" value="29.2" spread="11.0"/>
                    <measurement group_id="O4" value="22.6" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>bleeding only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3" spread="5.9"/>
                    <measurement group_id="O2" value="19.3" spread="8.8"/>
                    <measurement group_id="O3" value="18.6" spread="6.5"/>
                    <measurement group_id="O4" value="17.4" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>spotting only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" spread="7.0"/>
                    <measurement group_id="O2" value="11.9" spread="7.6"/>
                    <measurement group_id="O3" value="10.5" spread="8.2"/>
                    <measurement group_id="O4" value="5.2" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Withdrawal Bleeding</title>
        <description>Withdrawal bleedings were defined as bleedings while a participant takes placebo tablets.</description>
        <time_frame>At Cycle 4 (28 days per cycle)</time_frame>
        <population>FAS (Participants with data at Cycle 4)</population>
        <group_list>
          <group group_id="O1">
            <title>DRSP 1 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 1 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O2">
            <title>DRSP 2 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 2 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O3">
            <title>DRSP 3 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>1 tablet per day placebo for 28 days in each 28-day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Withdrawal Bleeding</title>
          <description>Withdrawal bleedings were defined as bleedings while a participant takes placebo tablets.</description>
          <population>FAS (Participants with data at Cycle 4)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Intracyclic Bleeding</title>
        <description>Intracyclic bleedings were defined as bleedings while a participant takes active drugs.</description>
        <time_frame>At Cycle 4 (28 days per cycle)</time_frame>
        <population>FAS (Participants with data at Cycle 4)</population>
        <group_list>
          <group group_id="O1">
            <title>DRSP 1 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 1 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O2">
            <title>DRSP 2 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 2 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O3">
            <title>DRSP 3 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>1 tablet per day placebo for 28 days in each 28-day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Intracyclic Bleeding</title>
          <description>Intracyclic bleedings were defined as bleedings while a participant takes active drugs.</description>
          <population>FAS (Participants with data at Cycle 4)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Non-heavy Intracyclic Bleeding</title>
        <description>Non-heavy bleedings were defined as those other than heavy bleeding (less or normal bleeding).</description>
        <time_frame>At Cycle 4 (28 days per cycle)</time_frame>
        <population>FAS (Participants with data at Cycle 4)</population>
        <group_list>
          <group group_id="O1">
            <title>DRSP 1 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 1 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O2">
            <title>DRSP 2 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 2 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O3">
            <title>DRSP 3 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>1 tablet per day placebo for 28 days in each 28-day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Non-heavy Intracyclic Bleeding</title>
          <description>Non-heavy bleedings were defined as those other than heavy bleeding (less or normal bleeding).</description>
          <population>FAS (Participants with data at Cycle 4)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Non-heavy Withdrawal Bleeding</title>
        <description>Non-heavy bleedings were defined as those other than heavy bleeding (less or normal bleeding).</description>
        <time_frame>At Cycle 4 (28 dyas per cycle)</time_frame>
        <population>FAS (Participants with data at Cycle 4)</population>
        <group_list>
          <group group_id="O1">
            <title>DRSP 1 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 1 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O2">
            <title>DRSP 2 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 2 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O3">
            <title>DRSP 3 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>1 tablet per day placebo for 28 days in each 28-day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Non-heavy Withdrawal Bleeding</title>
          <description>Non-heavy bleedings were defined as those other than heavy bleeding (less or normal bleeding).</description>
          <population>FAS (Participants with data at Cycle 4)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum Carbohydrate Antigen-125 (CA125) After 4-cycle Treatment</title>
        <description>CA125 is a laboratory parameter giving an indication of having tumor, whose elevated levels that were defined by a lab suggest a potential tumor.</description>
        <time_frame>From baseline to Cycle 4 (28 days per cycle)</time_frame>
        <population>FAS (Participants with data at Cycle 4)</population>
        <group_list>
          <group group_id="O1">
            <title>DRSP 1 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 1 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O2">
            <title>DRSP 2 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 2 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O3">
            <title>DRSP 3 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>1 tablet per day placebo for 28 days in each 28-day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum Carbohydrate Antigen-125 (CA125) After 4-cycle Treatment</title>
          <description>CA125 is a laboratory parameter giving an indication of having tumor, whose elevated levels that were defined by a lab suggest a potential tumor.</description>
          <population>FAS (Participants with data at Cycle 4)</population>
          <units>Units/L</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.78" lower_limit="-26.4" upper_limit="5.5"/>
                    <measurement group_id="O2" value="0.53" lower_limit="-17.4" upper_limit="184.9"/>
                    <measurement group_id="O3" value="-3.79" lower_limit="-35.6" upper_limit="32.5"/>
                    <measurement group_id="O4" value="0.89" lower_limit="-7.8" upper_limit="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum C-reactive Protein (CRP) After 4-cycle Treatment</title>
        <description>CRP is a laboratory parameter giving an indication of inflammation, whose elevated levels that were defined by a lab suggest a potential inflammation.</description>
        <time_frame>From baseline to Cycle 4 (28 days per cycle)</time_frame>
        <population>FAS (Participants with data at Cycle 4)</population>
        <group_list>
          <group group_id="O1">
            <title>DRSP 1 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 1 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O2">
            <title>DRSP 2 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 2 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O3">
            <title>DRSP 3 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>1 tablet per day placebo for 28 days in each 28-day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum C-reactive Protein (CRP) After 4-cycle Treatment</title>
          <description>CRP is a laboratory parameter giving an indication of inflammation, whose elevated levels that were defined by a lab suggest a potential inflammation.</description>
          <population>FAS (Participants with data at Cycle 4)</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.015" lower_limit="-0.31" upper_limit="0.85"/>
                    <measurement group_id="O2" value="0.042" lower_limit="-0.09" upper_limit="0.77"/>
                    <measurement group_id="O3" value="-0.014" lower_limit="-2.73" upper_limit="0.35"/>
                    <measurement group_id="O4" value="-0.175" lower_limit="-7.38" upper_limit="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum Estradiol Level After 4-cycle Treatment</title>
        <description>Estradiol is a predominant sex hormone that presents in female.</description>
        <time_frame>From baseline to Cycle 4 (28 days per cycle)</time_frame>
        <population>FAS (Participants with data at Cycle 4)</population>
        <group_list>
          <group group_id="O1">
            <title>DRSP 1 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 1 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O2">
            <title>DRSP 2 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 2 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O3">
            <title>DRSP 3 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>1 tablet per day placebo for 28 days in each 28-day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum Estradiol Level After 4-cycle Treatment</title>
          <description>Estradiol is a predominant sex hormone that presents in female.</description>
          <population>FAS (Participants with data at Cycle 4)</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.32" lower_limit="-341.5" upper_limit="968.9"/>
                    <measurement group_id="O2" value="-42.23" lower_limit="-336.8" upper_limit="329.0"/>
                    <measurement group_id="O3" value="-98.02" lower_limit="-477.8" upper_limit="231.2"/>
                    <measurement group_id="O4" value="49.20" lower_limit="-182.7" upper_limit="310.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum Progesterone Level at Cycle 4</title>
        <description>Progesterone is a steroid hormone involving in the female menstrual cycle, pregnancy, etc.</description>
        <time_frame>From baseline to Cycle 4 (28 days per cycle)</time_frame>
        <population>FAS (Participants with data at Cycle 4)</population>
        <group_list>
          <group group_id="O1">
            <title>DRSP 1 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 1 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O2">
            <title>DRSP 2 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 2 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O3">
            <title>DRSP 3 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>1 tablet per day placebo for 28 days in each 28-day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum Progesterone Level at Cycle 4</title>
          <description>Progesterone is a steroid hormone involving in the female menstrual cycle, pregnancy, etc.</description>
          <population>FAS (Participants with data at Cycle 4)</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.93" lower_limit="-22.2" upper_limit="6.3"/>
                    <measurement group_id="O2" value="-8.23" lower_limit="-23.6" upper_limit="5.7"/>
                    <measurement group_id="O3" value="-9.37" lower_limit="-22.3" upper_limit="6.7"/>
                    <measurement group_id="O4" value="-0.27" lower_limit="-20.6" upper_limit="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Change From Baseline for Total Pelvic Pain Score at Times Other Than During Menstruation at Cycle 4</title>
        <description>Total pelvic pain score was defined as sum of 2 sub-scores: severity of dysmenorrhea (none: 0, mild: 1, moderate: 2, severe: 3) and use of analgesics (none: 0, mild: 1, moderate: 2, severe: 3). Total possible best is 0, and total possible worst is 6.</description>
        <time_frame>From baseline to Cycle 4(28 days per cycle)</time_frame>
        <population>FAS (Participants with data at Cycle 4)</population>
        <group_list>
          <group group_id="O1">
            <title>DRSP 1 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 1 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O2">
            <title>DRSP 2 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 2 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O3">
            <title>DRSP 3 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>1 tablet per day placebo for 28 days in each 28-day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline for Total Pelvic Pain Score at Times Other Than During Menstruation at Cycle 4</title>
          <description>Total pelvic pain score was defined as sum of 2 sub-scores: severity of dysmenorrhea (none: 0, mild: 1, moderate: 2, severe: 3) and use of analgesics (none: 0, mild: 1, moderate: 2, severe: 3). Total possible best is 0, and total possible worst is 6.</description>
          <population>FAS (Participants with data at Cycle 4)</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="1.19"/>
                    <measurement group_id="O2" value="-0.3" spread="1.12"/>
                    <measurement group_id="O3" value="-0.1" spread="1.06"/>
                    <measurement group_id="O4" value="0.1" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Change From Baseline in Total Dysmenorrheal Score at Final Evaluation in Subgroups (1)</title>
        <description>Total dysmenorrheal score was defined as sum of 2 sub-scores: severity of dysmenorrhea (none: 0, mild: 1, moderate: 2, severe: 3) and use of analgesics (none: 0, mild: 1, moderate: 2, severe: 3). Total possible best is 0, and total possible worst is 6. Note: used with permission of Nobelpharma Co., Ltd. from the phase 3 clinical study protocol (Prog Med 2005:25 (3):739-758) of IKH-01 in dysmenorrhea (associated with endometriosis) (Nobelpharma Co., Ltd.)</description>
        <time_frame>Baseline and up to Cycle 4 (28 days per cycle)</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>DRSP 1 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 1 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O2">
            <title>DRSP 2 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 2 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O3">
            <title>DRSP 3 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>1 tablet per day placebo for 28 days in each 28-day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Dysmenorrheal Score at Final Evaluation in Subgroups (1)</title>
          <description>Total dysmenorrheal score was defined as sum of 2 sub-scores: severity of dysmenorrhea (none: 0, mild: 1, moderate: 2, severe: 3) and use of analgesics (none: 0, mild: 1, moderate: 2, severe: 3). Total possible best is 0, and total possible worst is 6. Note: used with permission of Nobelpharma Co., Ltd. from the phase 3 clinical study protocol (Prog Med 2005:25 (3):739-758) of IKH-01 in dysmenorrhea (associated with endometriosis) (Nobelpharma Co., Ltd.)</description>
          <population>FAS</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>age: &lt; 30 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="1.46"/>
                    <measurement group_id="O2" value="-2.4" spread="1.50"/>
                    <measurement group_id="O3" value="-1.9" spread="1.49"/>
                    <measurement group_id="O4" value="-1.2" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>age: &gt;= 30 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="1.54"/>
                    <measurement group_id="O2" value="-1.9" spread="1.49"/>
                    <measurement group_id="O3" value="-1.9" spread="1.75"/>
                    <measurement group_id="O4" value="-0.8" spread="1.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>weight: &lt; 50 kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="1.30"/>
                    <measurement group_id="O2" value="-2.4" spread="0.99"/>
                    <measurement group_id="O3" value="-1.5" spread="1.39"/>
                    <measurement group_id="O4" value="-0.7" spread="1.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>weight: &gt;= 50kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="1.57"/>
                    <measurement group_id="O2" value="-2.0" spread="1.64"/>
                    <measurement group_id="O3" value="-2.2" spread="1.74"/>
                    <measurement group_id="O4" value="-1.1" spread="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>functional dysmenorrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="1.63"/>
                    <measurement group_id="O2" value="-2.1" spread="1.52"/>
                    <measurement group_id="O3" value="-1.8" spread="1.73"/>
                    <measurement group_id="O4" value="-1.0" spread="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>organic dysmenorrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="1.00"/>
                    <measurement group_id="O2" value="-2.1" spread="1.49"/>
                    <measurement group_id="O3" value="-2.3" spread="1.37"/>
                    <measurement group_id="O4" value="-1.0" spread="1.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>with medical surgical history</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="1.62"/>
                    <measurement group_id="O2" value="-2.0" spread="1.50"/>
                    <measurement group_id="O3" value="-2.1" spread="1.61"/>
                    <measurement group_id="O4" value="-1.1" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>without medical surgical history</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" spread="1.42"/>
                    <measurement group_id="O2" value="-2.3" spread="1.53"/>
                    <measurement group_id="O3" value="-1.8" spread="1.66"/>
                    <measurement group_id="O4" value="-0.8" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Change From Baseline in Total Dysmenorrheal Score at Final Evaluation in Subgroups (2)</title>
        <description>Total dysmenorrheal score was defined as sum of 2 sub-scores: severity of dysmenorrhea (none: 0, mild: 1, moderate: 2, severe: 3) and use of analgesics (none: 0, mild: 1, moderate: 2, severe: 3). Total possible best is 0, and total possible worst is 6. Note: used with permission of Nobelpharma Co., Ltd. from the phase 3 clinical study protocol (Prog Med 2005:25 (3):739-758) of IKH-01 in dysmenorrhea (associated with endometriosis) (Nobelpharma Co., Ltd.)</description>
        <time_frame>Baseline and up to 4 Cycles (28 days per cycle)</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>DRSP 1 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 1 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O2">
            <title>DRSP 2 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 2 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O3">
            <title>DRSP 3 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>1 tablet per day placebo for 28 days in each 28-day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Dysmenorrheal Score at Final Evaluation in Subgroups (2)</title>
          <description>Total dysmenorrheal score was defined as sum of 2 sub-scores: severity of dysmenorrhea (none: 0, mild: 1, moderate: 2, severe: 3) and use of analgesics (none: 0, mild: 1, moderate: 2, severe: 3). Total possible best is 0, and total possible worst is 6. Note: used with permission of Nobelpharma Co., Ltd. from the phase 3 clinical study protocol (Prog Med 2005:25 (3):739-758) of IKH-01 in dysmenorrhea (associated with endometriosis) (Nobelpharma Co., Ltd.)</description>
          <population>FAS</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>with previous medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="1.53"/>
                    <measurement group_id="O2" value="-2.1" spread="1.51"/>
                    <measurement group_id="O3" value="-1.9" spread="1.63"/>
                    <measurement group_id="O4" value="-1.0" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>with pregnancy history</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="1.62"/>
                    <measurement group_id="O2" value="-1.9" spread="1.32"/>
                    <measurement group_id="O3" value="-2.2" spread="1.72"/>
                    <measurement group_id="O4" value="-1.0" spread="2.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>without pregnancy history</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="1.47"/>
                    <measurement group_id="O2" value="-2.2" spread="1.62"/>
                    <measurement group_id="O3" value="-1.8" spread="1.61"/>
                    <measurement group_id="O4" value="-1.0" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>with birth history</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="1.59"/>
                    <measurement group_id="O2" value="-2.1" spread="1.28"/>
                    <measurement group_id="O3" value="-2.3" spread="1.96"/>
                    <measurement group_id="O4" value="-1.1" spread="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>without birth history</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="1.49"/>
                    <measurement group_id="O2" value="-2.1" spread="1.62"/>
                    <measurement group_id="O3" value="-1.9" spread="1.55"/>
                    <measurement group_id="O4" value="-1.0" spread="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>total dysmenorrheal score at baseline: 3 or 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="1.28"/>
                    <measurement group_id="O2" value="-1.9" spread="1.36"/>
                    <measurement group_id="O3" value="-1.8" spread="1.44"/>
                    <measurement group_id="O4" value="-1.0" spread="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>total dysmenorrheal score at baseline: 5 or 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="1.75"/>
                    <measurement group_id="O2" value="-2.6" spread="1.77"/>
                    <measurement group_id="O3" value="-2.4" spread="2.06"/>
                    <measurement group_id="O4" value="-1.1" spread="1.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Change From Baseline in Total Dysmenorrheal Score at Final Evaluation in Patients Without Previous Medication</title>
        <description>Total dysmenorrheal score was defined as sum of 2 sub-scores: severity of dysmenorrhea (none: 0, mild: 1, moderate: 2, severe: 3) and use of analgesics (none: 0, mild: 1, moderate: 2, severe: 3). Total possible best is 0, and total possible worst is 6. Note: used with permission of Nobelpharma Co., Ltd. from the phase 3 clinical study protocol (Prog Med 2005:25 (3):739-758) of IKH-01 in dysmenorrhea (associated with endometriosis) (Nobelpharma Co., Ltd.)</description>
        <time_frame>Baseline and up to 4 Cycles (28 days per cycle)</time_frame>
        <population>The number of subjects without previous medication in DRSP 1 mg/EE 20 μg group was 1, so the standard deviation was not measurable. The number of subjects without previous medication in the other three groups were 0, so the data were not applicable.</population>
        <group_list>
          <group group_id="O1">
            <title>DRSP 1 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 1 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O2">
            <title>DRSP 2 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 2 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O3">
            <title>DRSP 3 mg/EE 20 μg</title>
            <description>1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>1 tablet per day placebo for 28 days in each 28-day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Dysmenorrheal Score at Final Evaluation in Patients Without Previous Medication</title>
          <description>Total dysmenorrheal score was defined as sum of 2 sub-scores: severity of dysmenorrhea (none: 0, mild: 1, moderate: 2, severe: 3) and use of analgesics (none: 0, mild: 1, moderate: 2, severe: 3). Total possible best is 0, and total possible worst is 6. Note: used with permission of Nobelpharma Co., Ltd. from the phase 3 clinical study protocol (Prog Med 2005:25 (3):739-758) of IKH-01 in dysmenorrhea (associated with endometriosis) (Nobelpharma Co., Ltd.)</description>
          <population>The number of subjects without previous medication in DRSP 1 mg/EE 20 μg group was 1, so the standard deviation was not measurable. The number of subjects without previous medication in the other three groups were 0, so the data were not applicable.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>DRSP 1 mg/EE 20 μg</title>
          <description>1 tablet per day Drospirenone (DRSP) 1 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
        </group>
        <group group_id="E2">
          <title>DRSP 2 mg/EE 20 μg</title>
          <description>1 tablet per day Drospirenone (DRSP) 2 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
        </group>
        <group group_id="E3">
          <title>DRSP 3 mg/EE 20 μg</title>
          <description>1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>1 tablet per day placebo for 28 days in each 28-day cycle</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma stage 0</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Henoch-Schonlein purpura</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="62"/>
                <counts group_id="E4" subjects_affected="53" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="62"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="63"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="62"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="28" subjects_affected="16" subjects_at_risk="62"/>
                <counts group_id="E2" events="32" subjects_affected="18" subjects_at_risk="63"/>
                <counts group_id="E3" events="31" subjects_affected="22" subjects_at_risk="62"/>
                <counts group_id="E4" events="30" subjects_affected="17" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="24" subjects_affected="17" subjects_at_risk="62"/>
                <counts group_id="E2" events="35" subjects_affected="24" subjects_at_risk="63"/>
                <counts group_id="E3" events="32" subjects_affected="24" subjects_at_risk="62"/>
                <counts group_id="E4" events="32" subjects_affected="26" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="62"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="63"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="62"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Prothrombin time shortened</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E4" events="6" subjects_affected="4" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Coagulation test abnormal</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="62"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="63"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="62"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="63"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="62"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="48" subjects_affected="21" subjects_at_risk="62"/>
                <counts group_id="E2" events="84" subjects_affected="28" subjects_at_risk="63"/>
                <counts group_id="E3" events="63" subjects_affected="30" subjects_at_risk="62"/>
                <counts group_id="E4" events="68" subjects_affected="23" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="30" subjects_affected="16" subjects_at_risk="62"/>
                <counts group_id="E2" events="26" subjects_affected="18" subjects_at_risk="63"/>
                <counts group_id="E3" events="47" subjects_affected="22" subjects_at_risk="62"/>
                <counts group_id="E4" events="58" subjects_affected="26" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" events="34" subjects_affected="20" subjects_at_risk="62"/>
                <counts group_id="E2" events="32" subjects_affected="18" subjects_at_risk="63"/>
                <counts group_id="E3" events="12" subjects_affected="8" subjects_at_risk="62"/>
                <counts group_id="E4" events="7" subjects_affected="4" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Breast discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Genital haemorrhage</sub_title>
                <counts group_id="E1" events="32" subjects_affected="20" subjects_at_risk="62"/>
                <counts group_id="E2" events="31" subjects_affected="19" subjects_at_risk="63"/>
                <counts group_id="E3" events="33" subjects_affected="23" subjects_at_risk="62"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor will confirm the contents before disclosure.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>BAYER</organization>
      <email>clinical-trials-contact@bayerhealthcare.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

